Rebus Holdings, Inc.

Equities

RBSH

US75619J1034

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 14:53:00 17/06/2024 BST			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	-98.04%

2023	Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
2023	Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Inspyr Therapeutics, Inc. Announces Board Changes

September 13, 2017 at 02:00 pm

Inspyr Therapeutics, Inc. announced that Bo Jesper Hansen is retiring from the company’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the company's Board of Directors.

Latest news about Rebus Holdings, Inc.

Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Rebus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Rebus Holdings, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	21/11/22	CI
Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Rebus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22	CI
Rebus Holdings, Inc. Auditor Raises 'Going Concern' Doubt	30/03/22	CI
Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
Inspyr Therapeutics Announces New Holding Company Structure	12/10/21	CI
Inspyr Therapeutics, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021	16/08/21	CI
Inspyr Therapeutics, Inc. Announces Resignation of Michael Cain as Chief Executive Officer	21/06/21	CI
Inspyr Therapeutics, Inc. announced that it has received $0.6 million in funding	17/06/21	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	17/05/21	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	31/03/21	CI
Inspyr Therapeutics, Inc. announced that it has received $0.5 million in funding	11/01/21	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20/11/20	CI
Inspyr Therapeutics, Inc. announced that it has received $0.5 million in funding	22/10/20	CI
Inspyr Therapeutics, Inc. Enters into Termination of License Agreement with Ridgeway Therapeutics, Inc	08/10/20	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	14/08/20	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	06/07/20	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	14/05/20	CI
Inspyr Therapeutics, Inc. announced that it has received $0.25 million in funding	05/03/20	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	20/12/19	CI

Chart Rebus Holdings, Inc.

Duration

Period

More charts

Company Profile

Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REBUS HOLDINGS, INC.	-98.04%	3.21K
VERTEX PHARMACEUTICALS INCORPORATED	+16.35%	122B
REGENERON PHARMACEUTICALS, INC.	+18.90%	113B
ARGENX SE	+2.77%	22.66B
BIONTECH SE	-16.44%	21.34B
WUXI APPTEC CO., LTD.	-39.57%	16.92B
BEIGENE, LTD.	-12.70%	16.68B
GENMAB A/S	-16.36%	16.61B
NEUROCRINE BIOSCIENCES, INC.	+3.27%	13.62B
SAREPTA THERAPEUTICS, INC.	+21.87%	11.04B

Bio Therapeutic Drugs